Ionis Pharmaceuticals (NASDAQ:IONS) on Wednesday reported a net loss of $229 million for its fourth quarter ended December 31, 2025.
The Carlsbad, California-based biotechnology company, focused on RNA-targeted drug discovery and development, said it had a loss of $1.41 per share.
When adjusted for non-cash stock-based compensation expense and other items, the loss was $1.14 per share.
Revenue for the period totaled $203 million, surpassing the average estimate of $155.6 million from seven analysts surveyed by Zacks Investment Research.
For the full year 2025, Ionis reported a net loss of $381 million, or $2.38 per share.
Revenue for the year was $944 million, reflecting contributions from commercial products such as Spinraza (nusinersen), royalties from partnered programs, and milestone payments tied to clinical and regulatory progress across its pipeline.
Looking ahead, Ionis provided full-year 2026 revenue guidance in the range of $800 million to $825 million.